



Defining Asthma: Clinical Criteria




From: Woolcock, A.J. "Asthma" in *Textbook of Respiratory Medicine*, 2nd ed. Murray, Nadel, eds. (Saunders: Philadelphia) pp. 1288-1330, 1994

Defining Asthma: Bronchial Hyperresponsiveness




Impaired Ventilation in Asthma




From: Klarreich, *Nature* 424:873, 2003

Dynamic Imaging of Asthma



Mucus Plugging is a Prominent Feature of Moderate to Severe Asthma




From: Bousquet et al., *Am. J. Respir. Crit. Care Med.*, 161:1720, 2000

Some Landmarks in the History of the Immunology of Asthma*

- 1989: Early genetic mapping assigns chromosome 5q to the "cytokine gene cluster."
- Early 1990s: Asthma is an inflammatory disease.
- 1990: Upregulation of ICAM-1 and LFA-1, adhesion molecules, in a primate model of asthma
- 1992: T_H2 bias of lymphocytes in asthma
- 1997: Experimental support grows for the "Hygiene hypothesis," first proposed in 1989.
- 2000: Role of Tregs in regulation of asthma


*Highly biased view

Nature of Inflammatory Cells in Biopsies From Airways of Asthmatics




From: Ollerenshaw and Woolcock., *Am. Rev. Resp. Dis.* 145:922, 1992

Defining Asthma: Pathological Features




From: Bousquet et al., *Am. J. Respir. Crit. Care Med.*, 161:1720, 2000

Pro-survival and Metaplastic Pathways to Goblet Cell Production




From: Cohn, *Am. J. Clin. Invest.* 116:306, 2006

Tissue "Compartments" in Asthma






Adhesion Molecules ICAM-1 and LFA-1 in Experimental Asthma



From: Wegner et al., *Science* 247:456, 1990


Asthma and the Immune Response




Asthma as a T_H2-dominated Disease

First Recognition of a T_H2 Bias in Lymphocytes Obtained by BAL in Asthmatics

From: Robinson et al., *New Engl. J. Med.* 326:298,1992




STAT-6 Signaling Pathways Leading to the Asthmatic Phenotype




From: Elias et al., *J. Clin. Invest.* 111:291, 2003

Defective Innate Immunity to Rhinovirus Infection in Asthmatics




From: Wark and Gibson, *Thorax* 61:909, 2006

Potential Drug Targets in Asthma



From: Barnes, *Nature Reviews Drug Discovery* 3:831, 2004

Understanding the Immunology of Asthma Leads to Insights Into Novel Therapeutics



From: Barnes, *Nature Reviews Drug Discovery* 3:831, 2004

Who Gets Asthma?

The Inverse Association Between Tuberculin Responses and Atopic Disorder
 Toshihiro Oikawa, Toshihiro Oikawa, Shirohisa Oikawa, Julian M. Hargrett

Background: Tuberculin responses are inversely associated with atopy. However, the mechanism of this association is unclear. We investigated the association between tuberculin responses and atopy in a population of children with allergic rhinitis and asthma.

Methods: We studied 100 children with allergic rhinitis and asthma. Tuberculin responses were measured by skin prick tests. Atopy was defined as the presence of IgE antibodies to at least one of the major allergens (dust mite, cat, dog, grass pollen, and birch pollen).

Results: Tuberculin responses were inversely associated with atopy. Children with high tuberculin responses had lower levels of IgE antibodies to allergens. This association was independent of age, sex, and season.

Conclusions: Tuberculin responses are inversely associated with atopy. This association may be mediated by the immune system.




Table 1. History of infectious diseases, atopic symptoms, IgE levels, and cytokine profiles in subjects grouped by tuberculin reactivity, ASE, allergen-specific IgE, LD, undetectable.

Measurement	Group 1 (n = 290)	Group 2 (n = 289)	Group 3 (n = 213)	Group 4 (n = 79)	Total (n = 867)
Tuberculin response					
At 6 years	-	-	+	+	
At 12 years	-	+	+	+	
Positive antiviral immunity (%)					
Measles (history + vaccine)	83.4	87.2	84.5	81.3	84.3
Chicken pox (history + vaccine)	86.9	85.3	82.2	82.7	83.9
Mumps (history + vaccine)	62.8	60.9	60.1	57.3	61.0
Number with IgE to Ascaris	2	2	2	1	7
Symptoms (%)					
Atopy (past + present)	46.8	33.9 ^{††}	25.8 ^{†††}	38.7	36.6
Atopy (present)	32.1	7.9 ^{††††}	9.8 ^{††††}	30.7	18.5
Asthma (past + present)	13.4	4.1 ^{††}	3.7 ^{††}	6.8	7.4
Rhinitis (past + present)	16.2	4.8 ^{††}	8.8 ^{††}	14.6	10.4
Eczema (past + present)	22.7	12.8 ^{††}	12.2 ^{††}	16.0	16.2
Geometric mean IgE (IU/ml)	208	149 ^{**}	95 ^{***}	178	154
Positive ASE (%)	55.8	43.9 ^{††}	41.8 ^{††}	53.3	48.2
Atopic high IgE or positive ASE (%)	65.5	54.0 ^{††}	49.2 ^{††}	61.3	57.3
Median cytokine level (pg/ml)					
IL-4	1.88	0.96 [†]	0.92 [†]	1.66	1.22 (10.2-UD) [§]
IL-13	18.3	10.2 ^{†††}	7.8 ^{†††}	19.1	14.2 (45.6-UD)
IL-10	5.9	3.1 ^{†††}	2.9 ^{†††}	5.9	3.8 (10.2-UD)
IL-12	UD	UD	UD	UD	UD
IFN- γ	7.8	11.0 ^{††}	13.2 ^{††}	6.4	10.5 (23.2-UD)
Positive family history within three generations (%)	54.1	49.8	49.8	48.0	51.0
Mean BMI	21.1	22.0	21.9	21.2	21.6

^{††} $P < 0.01$, ^{†††} $P < 0.001$ on the basis of Student's test. ^{††††} $P < 0.05$, ^{†††††} $P < 0.01$, ^{††††††} $P < 0.001$ on the basis of a median test. ^{*} $P < 0.05$, ^{**} $P < 0.01$, ^{***} $P < 0.001$ on the basis of χ^2 against group 1, respectively. (Maximum values.)


From: Shirakawa et al., *Science* 275:77, 1997

Table 2. Odds ratios for atopy and for occurrence and remission of atopic symptoms in positive versus negative tuberculin responders by age. Multiple logistic analysis was conducted with the SPSSX package, version 2.2. In all models, allowance was made for dichotomized variables including sex, life-style, nutritional status, environmental factors, and family history. Only significant values are shown.

Tuberculin response	Odds ratio		
	Atopy	Occurrence	Remission
Conversion to positive up to 6 years of age	0.50 (0.29 to 0.83) [*]	Asthma: 0.31 (0.22 to 0.45) ^{**} Eczema: 0.50 (0.33 to 0.91) [*]	Asthma: 8.2 (6.0 to 9.9) ^{**} Eczema: 1.6 (1.0 to 2.2) [*]
Conversion to positive between 6 and 12 years of age	0.43 (0.25 to 0.83) ^{**}	Asthma: 0.42 (0.24 to 0.56) ^{**}	Asthma: 6.0 (2.8 to 10.3) ^{***} Eczema: 6.7 (4.8 to 11.4) ^{***} Rhinitis: 9.0 (6.2 to 14.2) ^{***}

^{*} $P < 0.05$, ^{**} $P < 0.01$, ^{***} $P < 0.005$.

From: Shirakawa et al., *Science* 275:77, 1997



Asthma, rhinitis, other respiratory diseases

Hay fever and asthma in relation to markers of infection in the United States

Pavlo Maria Martovani, MD,¹ Francesco Rosmini, DSc,² Valentin Panait, DSc,³ Ligia Fortuna, BS,⁴ and Sergio Busceti, MD,⁵ PhD,⁶ July 2007


Background: The hygiene hypothesis posits that declining rates of infectious diseases in industrialized nations are linked to the increased prevalence of allergic diseases. The hygiene hypothesis is supported by the fact that children in developing countries, who are exposed to a wider range of infectious agents, have lower rates of allergic diseases. However, the hygiene hypothesis is controversial because it does not explain the increasing prevalence of allergic diseases in industrialized nations that have high rates of infectious diseases. We investigated the relationship between markers of infection and allergic diseases in the United States.

Methods: We conducted a cross-sectional study of 1,000 children aged 5 to 14 years in the United States. We measured the prevalence of allergic diseases (asthma, rhinitis, eczema) and markers of infection (antibodies to various pathogens). We used logistic regression to analyze the relationship between markers of infection and allergic diseases, adjusting for age, sex, and other factors.

Results: We found that children with markers of infection had a lower prevalence of allergic diseases. Specifically, children with markers of infection had a 30% lower prevalence of asthma, a 20% lower prevalence of rhinitis, and a 15% lower prevalence of eczema. These associations remained significant after adjusting for age, sex, and other factors.


Conclusions: Our findings support the hygiene hypothesis, suggesting that markers of infection are inversely associated with allergic diseases in the United States. This relationship may be mediated by the immune system's response to infections, which may lead to a more balanced immune response and a lower prevalence of allergic diseases.

From: Journal of Allergy and Clinical Immunology, Volume 120, Number 5, November 2007, Pages 1000-1006




An Alternative to the Hygiene Hypothesis: Regulatory T-cells

The Role of Regulatory T-cells in Modifying T_H2 Immunity



Modified from: Maizels & Yazdanbakhsh, *Nature Rev. Immunol.* 3:733, 2003


Immunotherapy of Atopic Diseases: a Role for Tregs?



Following 2-year grass pollen immunotherapy (dosed circles), there were significant increases in (A) allergen-stimulated PBMC production of IL-10; (B) serum concentrations of grass pollen allergen-specific IgG4; and (C) serum inhibitory activity for allergen-IgE binding to B cells compared with controls (open circles). These changes were accompanied by a reduction in symptoms and inhibition allergen-induced late cutaneous response.

From: Robinson et al., *J. Clin. Invest* 114:1389, 2004


Regulatory T-cells (Tregs) in Asthma





From: Robinson et al., *J. Clin. Invest* 114:1389, 2004

Chemokines: the Gatekeepers of Inflammation

Chemokines Direct Traffic




From: Luster, *Curr. Opin. Immunol.* 14:129, 2002




From: Barnes, *Nature Reviews Drug Discovery* 3:831,2004

Inflammatory Mediators as Novel Drug Targets




From: Luster and Tager *Nature Reviews Immunol.* 4:711, 2004



From: Tilley and Boucher *J. Clin. Invest.* 115:13-16 (2005)

Adenosine Receptors as Drug Targets in Asthma

Pro- and Anti-inflammatory Activities of Adenosine in Asthma



From: Tilley and Boucher
J. Clin. Invest. 115:13-16 (2005)

Pharmacogenetics: The Future of Asthma Therapeutics?

Summary of Genes Associated With Atopy

Gene	Chromosome	Phenotype	Genetic association	Association	Reference
IL13	1q21	Total IgE, eosinophilia	Major histocompatibility complex	Yes	[24]
D13S253	1q21	Asthma, leukocytosis	HLA-DQA1	Yes	[25]
LEK1	2q14	Asthma	HLA-DQB1	Yes	[26]
C12A1	2q33	Asthma severity	-1382C>T	Yes	[27]
CTSLA	2q33	Diff. asthma	-1143C>T	Yes	[28]
IL4	5q31	Asth	HLA-DP1	Yes	[29]
IL13	5q31	Asth	HLA-DP1	Yes	[30]
IL13	5q31	Asth	HLA-DP1	Yes	[31]
CD14	5q31	Asth, asthma, BHR, IgE, AD, Allergic Rhinitis	-1132C>T	No	[32]
IGHE1	5q31.34	Asth	-1132C>T	Yes	[33]
IGHE1	5q31.34	Asth	-1132C>T	Yes	[34]
IL13R	5q31.34	Asth	-1132C>T	Yes	[35]
IL13R	5q31.34	Asth	-1132C>T	Yes	[36]
IL13R	5q31.34	Asth	-1132C>T	Yes	[37]
IL13R	5q31.34	Asth	-1132C>T	Yes	[38]
IL13R	5q31.34	Asth	-1132C>T	Yes	[39]
IL13R	5q31.34	Asth	-1132C>T	Yes	[40]
IL13R	5q31.34	Asth	-1132C>T	Yes	[41]
IL13R	5q31.34	Asth	-1132C>T	Yes	[42]
IL13R	5q31.34	Asth	-1132C>T	Yes	[43]
IL13R	5q31.34	Asth	-1132C>T	Yes	[44]
IL13R	5q31.34	Asth	-1132C>T	Yes	[45]
IL13R	5q31.34	Asth	-1132C>T	Yes	[46]
IL13R	5q31.34	Asth	-1132C>T	Yes	[47]
IL13R	5q31.34	Asth	-1132C>T	Yes	[48]
IL13R	5q31.34	Asth	-1132C>T	Yes	[49]
IL13R	5q31.34	Asth	-1132C>T	Yes	[50]
IL13R	5q31.34	Asth	-1132C>T	Yes	[51]
IL13R	5q31.34	Asth	-1132C>T	Yes	[52]
IL13R	5q31.34	Asth	-1132C>T	Yes	[53]
IL13R	5q31.34	Asth	-1132C>T	Yes	[54]
IL13R	5q31.34	Asth	-1132C>T	Yes	[55]
IL13R	5q31.34	Asth	-1132C>T	Yes	[56]
IL13R	5q31.34	Asth	-1132C>T	Yes	[57]
IL13R	5q31.34	Asth	-1132C>T	Yes	[58]
IL13R	5q31.34	Asth	-1132C>T	Yes	[59]
IL13R	5q31.34	Asth	-1132C>T	Yes	[60]
IL13R	5q31.34	Asth	-1132C>T	Yes	[61]
IL13R	5q31.34	Asth	-1132C>T	Yes	[62]
IL13R	5q31.34	Asth	-1132C>T	Yes	[63]
IL13R	5q31.34	Asth	-1132C>T	Yes	[64]
IL13R	5q31.34	Asth	-1132C>T	Yes	[65]
IL13R	5q31.34	Asth	-1132C>T	Yes	[66]
IL13R	5q31.34	Asth	-1132C>T	Yes	[67]
IL13R	5q31.34	Asth	-1132C>T	Yes	[68]
IL13R	5q31.34	Asth	-1132C>T	Yes	[69]
IL13R	5q31.34	Asth	-1132C>T	Yes	[70]
IL13R	5q31.34	Asth	-1132C>T	Yes	[71]
IL13R	5q31.34	Asth	-1132C>T	Yes	[72]
IL13R	5q31.34	Asth	-1132C>T	Yes	[73]
IL13R	5q31.34	Asth	-1132C>T	Yes	[74]
IL13R	5q31.34	Asth	-1132C>T	Yes	[75]
IL13R	5q31.34	Asth	-1132C>T	Yes	[76]
IL13R	5q31.34	Asth	-1132C>T	Yes	[77]
IL13R	5q31.34	Asth	-1132C>T	Yes	[78]
IL13R	5q31.34	Asth	-1132C>T	Yes	[79]
IL13R	5q31.34	Asth	-1132C>T	Yes	[80]
IL13R	5q31.34	Asth	-1132C>T	Yes	[81]
IL13R	5q31.34	Asth	-1132C>T	Yes	[82]
IL13R	5q31.34	Asth	-1132C>T	Yes	[83]
IL13R	5q31.34	Asth	-1132C>T	Yes	[84]
IL13R	5q31.34	Asth	-1132C>T	Yes	[85]
IL13R	5q31.34	Asth	-1132C>T	Yes	[86]
IL13R	5q31.34	Asth	-1132C>T	Yes	[87]
IL13R	5q31.34	Asth	-1132C>T	Yes	[88]
IL13R	5q31.34	Asth	-1132C>T	Yes	[89]
IL13R	5q31.34	Asth	-1132C>T	Yes	[90]
IL13R	5q31.34	Asth	-1132C>T	Yes	[91]
IL13R	5q31.34	Asth	-1132C>T	Yes	[92]
IL13R	5q31.34	Asth	-1132C>T	Yes	[93]
IL13R	5q31.34	Asth	-1132C>T	Yes	[94]
IL13R	5q31.34	Asth	-1132C>T	Yes	[95]
IL13R	5q31.34	Asth	-1132C>T	Yes	[96]
IL13R	5q31.34	Asth	-1132C>T	Yes	[97]
IL13R	5q31.34	Asth	-1132C>T	Yes	[98]
IL13R	5q31.34	Asth	-1132C>T	Yes	[99]
IL13R	5q31.34	Asth	-1132C>T	Yes	[100]

From: Halapi and Hakonarson,
Curr. Opin. Pulm. Med. 10:22, 2003

BRD1, bronchodilator hypersensitivity; AD, allergic dermatitis; PAF, lysophosphatidylcholine; RCT, nasal respiratory viruses; SI, sinusitis.

Summary

1. Asthma is a chronic disease of the airways characterized by reversible airway obstruction, bronchial hyperactivity, chronic inflammation, and mucus hypersecretion.
2. The allergic response is characterized by an early phase, dominated by degranulation of mast cells, followed by a late phase, involving T cells and eosinophils.
3. Asthma is accompanied by up-regulation of leukocyte adhesion molecules and the presence of multiple pro-inflammatory mediators, including chemokines, prostaglandins, leukotrienes, adenosine, and toxic products released from eosinophil granules.
4. Asthma is a prototypical Th2 disease, with increased production of IL-4 and IL-13, and STAT6 activation. The immunobiology of asthma is highly complex, but includes defects in the anti-viral response in airway epithelia.
5. The hygiene hypothesis states that asthma may arise from an imbalance in the Th1 and Th2 lymphocyte populations, possibly from differences in exposure to Th1-polarizing stimuli early in life.
6. An alternative view is that asthma arises from a defect in immune regulation. Insufficient production of Tregs may predispose to airway sensitization and atopy.
7. Future insights into the cellular immunology and genetics underlying asthma offer hope for future therapeutics.